The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,810.00
Bid: 1,811.00
Ask: 1,811.50
Change: 0.00 (0.00%)
Spread: 0.50 (0.028%)
Open: 1,805.00
High: 1,812.50
Low: 1,797.00
Prev. Close: 1,810.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Berenberg - Buy Dignity; Liberum - Buy Genus

Fri, 01st Jul 2016 08:51

LONDON (Alliance News) - The following shares received analyst recommendations Friday morning:
----------
FTSE 100
----------
JPMORGAN RAISES SMITH & NEPHEW PRICE TARGET TO 1196 (1096) PENCE - 'NEUTRAL'
----------
Investec Ups Diageo Target To 2,300p From 2,160p, Keeps Buy
----------
CITIGROUP RAISES GLAXOSMITHKLINE PRICE TARGET TO 1800 (1550) PENCE - 'BUY'
----------
CREDIT SUISSE RAISES ROLLS ROYCE PRICE TARGET TO 590 (534.3) PENCE - 'UNDERP.'
----------
CREDIT SUISSE CUTS ITV PRICE TARGET TO 200 (255) PENCE - 'OUTPERFORM'
----------
HSBC CUTS ITV PRICE TARGET TO 200 (280) PENCE - 'BUY'
----------
BERENBERG CUTS SKY PRICE TARGET TO 730 (784) PENCE - 'SELL'
----------
GOLDMAN RAISES MONDI PRICE TARGET TO 1325 (1250) PENCE - 'NEUTRAL'
----------
BERENBERG CUTS JOHNSON MATTHEY PRICE TARGET TO 3250 (3865) PENCE - 'BUY'
----------
UBS RAISES OLD MUTUAL PRICE TARGET TO 210 (200) PENCE - 'BUY'
----------
UBS CUTS AVIVA PRICE TARGET TO 400 (455) PENCE - 'NEUTRAL'
----------
UBS CUTS DIRECT LINE PRICE TARGET TO 352 (390) PENCE - 'NEUTRAL'
----------
UBS RAISES CARNIVAL PLC PRICE TARGET TO 4050 (3850) PENCE - 'BUY'
----------
FTSE 250
----------
JPMORGAN CUTS JOHN WOOD GROUP PRICE TARGET TO 570 (600) PENCE - 'NEUTRAL'
----------
JPMORGAN CUTS HOWDEN JOINERY TO 'NEUTRAL' ('OVERWEIGHT') - TARGET 390 (570) PENCE
----------
JPMORGAN CUTS GREENE KING PRICE TARGET TO 950 (1050) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES SERCO GROUP PRICE TARGET TO 133 (130) PENCE - 'NEUTRAL'
----------
JPMORGAN CUTS GO-AHEAD GROUP PRICE TARGET TO 2390 (2427) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES NATIONAL EXPRESS PRICE TARGET TO 397 (362) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES FIRSTGROUP PRICE TARGET TO 145 (141) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS STAGECOACH GROUP TO 'UNDERWEIGHT' ('NEUTRAL'), PRICE TARGET 180 (256) PENCE
----------
JPMORGAN RAISES DAIRY CREST GROUP TO 'OVERWEIGHT' ('NEUTRAL')
----------
CITIGROUP RAISES SAFESTORE PRICE TARGET TO 440 (400) PENCE - 'BUY'
----------
PANMURE INITIATES TULLOW OIL PLC WITH 'SELL' - TARGET 210 PENCE
----------
CREDIT SUISSE RAISES TULLOW OIL PRICE TARGET TO 370 (330) PENCE - 'OUTPERFORM'
----------
Cantor Cuts Tullow Oil To Sell From Hold, Keeps Target At 163p
----------
CANACCORD CUTS MARSHALLS GROUP TO 'HOLD' ('BUY')
----------
Liberum Ups Tate & Lyle Target To 790p From 730p, Keeps Buy
----------
Liberum Ups Genus To Buy From Hold, Target To 1,750p From 1,500p
----------
GOLDMAN CUTS DS SMITH PRICE TARGET TO 390 (395) PENCE - 'NEUTRAL'
----------
TRADERS: MERRILL LYNCH RAISES ABERDEEN ASSET MANAGEMENT TO 'BUY' ('UNDERPERFORM')
----------
BERENBERG CUTS DOMINO'S PIZZA PRICE TARGET TO 400 (1200) PENCE - 'BUY'
----------
BERENBERG RAISES DIGNITY TO 'BUY' ('HOLD') - TARGET 2825 (2400) PENCE
----------
TRADERS: MACQUARIE INITIATES RIGHTMOVE WITH 'NEUTRAL'
----------
MAIN MARKET AND AIM
----------
JPMORGAN CUTS MOTHERCARE PRICE TARGET TO 180 (201) PENCE - 'OVERWEIGHT'
----------
Investec Ups Wynnstay Group To Hold From Sell, Cuts Target to 422p From 485p
----------
BERENBERG CUTS STAFFLINE TO 'HOLD' ('BUY') - TARGET 900 (1700) PENCE
----------
BERENBERG CUTS INTERSERVE TO 'HOLD' ('BUY') - TARGET 330 (520) PENCE
----------
Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.